Letter to the CDC and FDA Regarding Recent Health Advisory on Clusters of Patients with Adverse Events From Certain Botulinum Toxin Injections
View CDC/FDA letter
View press release
View CDC response letter, June 6, 2024
In a letter to the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA), Public Citizen asked that a recent health advisory regarding what the advisory characterized as “counterfeit or mishandled” injections of botulinum toxin be revised to ensure that clinicians err on the side of suspecting iatrogenic botulism in all patients experiencing adverse effects consistent with the distant spread of the botulinum toxin. The letter also asked the agencies to consider the possibility of iatrogenic botulism from recommended doses of approved and properly administered botulinum toxin drugs.
View our work related to botulinum-toxin products.